Afficher la notice abrégée

Outcome Of Patients With Sarcoidosis Refractory To Tnf Antagonists: A Case Series

dc.rights.licenseopenen_US
dc.contributor.authorTHERY-CASARI, C.
dc.contributor.authorJAMILLOUX, Y.
dc.contributor.authorBOUVRY, D.
dc.contributor.authorCHAPELON-ABRIC, C.
dc.contributor.authorMARQUET, A.
dc.contributor.authorBIELEFELD, P.
dc.contributor.authorSCHLEINITZ, N.
dc.contributor.authorVUKUSIC, S.
dc.contributor.authorGIRSZYN, N.
dc.contributor.authorFAIN, O.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorVALEYRE, D.
dc.contributor.authorSEVE, P.
dc.date.accessioned2021-01-05T15:53:27Z
dc.date.available2021-01-05T15:53:27Z
dc.date.issued2018-11-28
dc.identifier.issn1124-0490en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23677
dc.description.abstractEnBackground: Tumor necrosis factor (TNF) antagonists have been reported as an efficient third-line therapy for sarcoidosis but there is no data regarding patients who do not respond to this treatment. Objective: To report the characteristics, the outcome and the response to therapy of patients with sarcoidosis resistant to TNF antagonists. Methods: Patients from the French STAT (Sarcoidosis Treatment with Anti-TNF) registry who were classified as non-responders and who were followed-up for >1 year were included. The response to further therapies was classified as complete response, or partial response, and the others were classified as non-responders. Results: Among the 132 patients from the registry, 14 were considered as non-responders to anti-TNF. Nine patients (66% of women; mean age 48 years) were analyzed. The mean number of organs involved was 4.2. Seven patients were previously treated with more than 2 immunosuppressive treatments. The mean duration of the anti-TNF treatment was 9 months (range, 3-24). After a mean follow-up duration of 58 months (median, 35; range, 19-128) a complete response was observed in 2/9 cases, a partial response in 5/9 cases, and 2/9 cases were considered as non-responders. In all but one patient, the immunosuppressant that allowed the clinical response had previously been used. Furthermore, the dosage was not necessarily increased to gain efficacy. Non-responders were treated by corticosteroids only because of their comorbidities or noncompliance. Conclusion: In patients who do not respond to TNF antagonists, previously used immunosuppressants may be useful. Excluding a differential diagnosis, assessing compliance and testing for anti-drug antibodies should be systematic.
dc.language.isoENen_US
dc.subject.enMORPH3Eus
dc.title.enOutcome Of Patients With Sarcoidosis Refractory To Tnf Antagonists: A Case Series
dc.title.alternativeSarcoidosis Vasc Diffus Lung Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.36141/svdld.v35i4.6999en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32476925en_US
bordeaux.journalSarcoidosis Vasculitis and Diffuse Lung Diseasesen_US
bordeaux.page371-375en_US
bordeaux.volume35en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03098276
hal.version1
hal.date.transferred2021-01-05T15:53:30Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Sarcoidosis%20Vasculitis%20and%20Diffuse%20Lung%20Diseases&rft.date=2018-11-28&rft.volume=35&rft.issue=4&rft.spage=371-375&rft.epage=371-375&rft.eissn=1124-0490&rft.issn=1124-0490&rft.au=THERY-CASARI,%20C.&JAMILLOUX,%20Y.&BOUVRY,%20D.&CHAPELON-ABRIC,%20C.&MARQUET,%20A.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée